Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
about
Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infectionEsophageal cell proliferation in gastroesophageal reflux disease: clinical-morphological data before and after pantoprazoleQuantification of dental erosions in patients with GERD using optical coherence tomography before and after double-blind, randomized treatment with esomeprazole or placebo.Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux diseaseInhibition of gastric perception of mild distention by omeprazole in volunteersPharmacokinetics and pharmacodynamics of the proton pump inhibitors.Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers.Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial.Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitisA review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitorComparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: a randomized, double-blind, controlled studyEsomeprazole: a proton pump inhibitor.Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver FailureEsomeprazole: potent acid suppression in the treatment of acid-related disorders.Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.Management of reflux esophagitis: does the choice of proton pump inhibitor matter?Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.Formulation Development, Process Optimization, and In Vitro Characterization of Spray-Dried Lansoprazole Enteric Microparticles.Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionAcid control with esomeprazole and lansoprazole: a comparative dose-response study.Longitudinal study of gastroesophageal reflux and erosive tooth wear.A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.Esomeprazole formulary exclusion: impact on total health care services use and costs.A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.Pharmacokinetics of esomeprazole following varying intravenous administration rates.[A case of postoperative pulmonary metastasis of breast cancer treated with docetaxel and cyclophosphamide therapy].A pilot study comparing the effect of orally administered esomeprazole and omeprazole on gastric fluid pH in horses.Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.
P2860
Q26849521-BA106938-187F-4A32-A2F6-2B103DCD2A02Q33413173-1EA2E5CA-55FB-4F51-8A3F-D2EB7D82C3F2Q34206222-5AF51018-517B-4E60-ADF8-ABB6CED6DAC4Q35987371-F76262CB-9A52-4BE2-ACF0-B9C695587E52Q36351909-87D3FD1F-A968-4F98-80E8-CADD130B135EQ36542670-DB008A2E-26C6-428D-B758-445976CA4733Q36808048-CE5F4D20-9181-4B45-A9F1-F8359F72DCD2Q36924620-893F7E73-A1F2-430F-A417-3A55808AE06EQ36932316-02AE486E-605D-471E-AB69-A50C59DAB407Q37122451-30632FE9-1EFA-4A3E-8ED7-34F6BE065BB4Q37160360-D00594F6-36D3-4E3D-8F33-B92B873C473FQ37187264-920CE305-86E3-4559-A192-849096AEDA49Q37237706-2DF36142-2D2C-43EF-9FC2-D7AC11DB3CA0Q37390644-0A6DBFD0-3F2C-446B-BB2F-AAD4AC9D8056Q37707450-46513586-C92C-4791-9D6F-FA66BD14750BQ37755220-BBDF36B3-4BBB-4B6D-B02A-E77E0E1E135FQ38229080-53B6B19C-B385-40C8-B11E-58F596D7EBB8Q39360558-1AA929CF-CB13-432D-A02F-2EFBFA180C1FQ41343848-C6E7A09D-06A9-455E-9A6A-2EF422C42610Q41404243-979B0384-4C42-4133-B27A-30A49556A03CQ41634946-A28A295E-6F82-4338-942D-2D41D99A5E34Q42275708-4EA3057A-854D-4EF2-A3F1-A99DB01CBD5EQ42283418-F4AAC922-98E0-487D-BFAB-63A0E287FE30Q42371575-0EB59BA7-09ED-4B49-9A6F-C43ADB853A55Q42613192-F7EA0BDD-8C99-4876-99B1-B177AC1541A3Q42628118-B7CE3E06-5A5E-4524-AAE9-423FD910FDF5Q42662159-D9A33C65-1E99-4F75-A049-63761E142BCEQ42770379-ED14E5DA-545F-4A98-9A0A-A92C7352F604Q43055360-D2155528-F53F-4E2D-BEAB-F4A21275072AQ43195744-0ABB8C21-5D9D-41A5-A9F0-B89305769A53Q45125140-C6549650-05D7-4E08-B5BC-0E095421262AQ45264297-112AFB07-ED62-4275-9413-F40468756AC3Q45852987-97113EB2-9D68-4C18-A858-A36E6DED772CQ46383718-6DBA4AD5-897F-4A89-86C4-858C280858F8Q46424960-902D6EDC-B945-49D3-ACBB-3FD6CD41463FQ46447268-1758A166-E984-4852-A58E-C42F14C90694Q46858378-78EA9B1F-A5B8-49F1-B84C-B4D9652790B1Q46949951-09AA338E-7A09-4CB5-9FA9-CFF9A4F0D08BQ47958690-4DA83005-77DB-40CD-830E-41732C529E14Q49630186-8434B135-C064-4A91-91C6-58482DA7ADF0
P2860
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@en
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@nl
type
label
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@en
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@nl
prefLabel
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@en
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@nl
P2093
P1476
Esomeprazole 40 mg provides mo ...... o-oesophageal reflux symptoms.
@en
P2093
Clive Wilder-Smith
Kerstin Röhss
P2888
P304
P356
10.1007/S00228-004-0804-6
P577
2004-09-02T00:00:00Z
P6179
1046757764